The Oncology Institute appoints Jeremy Castle as COO with $375K base salary

Oncology Institute, Inc.

Jeremy N. Castle appointed COO effective September 5, 2023, replacing Matthew Miller, MD who departed June 16, 2023.
Castle previously served as VP of Operations at OneOncology (Jan 2022-Aug 2023); over 15 years in healthcare operations.
Base salary $375,000; target annual bonus 40% of base; $50,000 signing/relocation bonus.
Employment agreement has three-year initial term; severance of three months salary/COBRA if terminated without cause or for good reason.
No family relationships with directors/officers; no related party transactions required to be disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeremy N. Castle

Chief Operations Officer

TOI · Oncology Institute, Inc.

Effective: 2023-09-05
Filed: September 6, 2023, 7:59 PM ET

On September 5, 2023, The Oncology Institute, Inc., a Delaware corporation (the “Company”), appointed Jeremy N. Castle to replace Matthew Miller, MD as the Company’s Chief Operations Officer.

Departed

Matthew Miller, MD

Chief Operations Officer

TOI · Oncology Institute, Inc.

Effective: 2023-06-16
Successor: Jeremy N. Castle
Filed: September 6, 2023, 7:59 PM ET

Dr. Miller’s separation from the Company was effective June 16, 2023, as previously disclosed in that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jeremy N. Castle was appointed as Chief Operations Officer at Oncology Institute, Inc..

Action: appointed
Role: Chief Operations Officer

Exact text from the filing

On September 5, 2023, The Oncology Institute, Inc., a Delaware corporation (the “Company”), appointed Jeremy N. Castle to replace Matthew Miller, MD as the Company’s Chief Operations Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Matthew Miller, MD departed as Chief Operations Officer at Oncology Institute, Inc..

Action: separated
Role: Chief Operations Officer

Exact text from the filing

Dr. Miller’s separation from the Company was effective June 16, 2023, as previously disclosed in that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2023.

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001799191-23-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.